Show simple item record

dc.contributor.authorBozcan, Semih
dc.date.accessioned2023-09-26T10:54:21Z
dc.date.available2023-09-26T10:54:21Z
dc.date.submitted2020-12-07
dc.date.issued1987
dc.identifier.urihttps://acikbilim.yok.gov.tr/handle/20.500.12812/745519
dc.description.abstract- 77 - SUMMARY Labetalol, a a -and B - adrenoceptor blokcing drug, has been used in the treatment of hipertension in a total of kO patients. Heamudynamic effects, clinical pharmacology, plasma lipid effects, side effects, drug interections, and clinical use of labetalol has been reviewed. During the 8 weeks adose of 200-U0Ü mg labetalol daily produced a statistically significant reduction at the systolic blood pressure, both at sitting and supine position. Heart failure and non-speaific side effects uas the reason for stopping treatment in three patientB. No orthostatic hypotension has been observed. It can be concluded that labetalol is an effective and safe drug in the menagement of mild hypertension especielly in cases where beta blocking agents are patentially hazardous.en_US
dc.languageTurkish
dc.language.isotr
dc.rightsinfo:eu-repo/semantics/embargoedAccess
dc.rightsAttribution 4.0 United Statestr_TR
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subjectKardiyolojitr_TR
dc.subjectCardiologyen_US
dc.titleLabetalol Hidroklorid'in primer ve sekonder hipertansiyon üzerine etkisi
dc.typedoctoralThesis
dc.date.updated2020-12-07
dc.contributor.departmentDahiliye Ana Bilim Dalı
dc.subject.ytmHypertension
dc.subject.ytmLabetalol
dc.identifier.yokid60658
dc.publisher.instituteİstanbul Şişli Hamidiye Etfal Eğitim ve Araştırma Hastanesi
dc.publisher.universityDİĞER (KURUMLAR, HASTANELER VB.)
dc.type.submedicineThesis
dc.identifier.thesisid60658
dc.description.pages84
dc.publisher.disciplineDiğer


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

info:eu-repo/semantics/embargoedAccess
Except where otherwise noted, this item's license is described as info:eu-repo/semantics/embargoedAccess